The course of Jeremy Skillington’s year took a fateful turn in March when he took a call from Cathal Friel, chairman of Open Orphan, a clinical trials company listed on the Alternative Investment Market (AIM). At the time Skillington was tidying up the loose ends of the landmark €380 million sale of Irish biotech company Inflazome to Roche, a Swiss pharmaceutical multinational, and plotting three months of leisure.
Donegal deal-maker Friel dangled the dizzying prospect of heading an Irish biotech company that would list on the stock market within three to six months.
Link here for the full article